Additionally, many patients report that carbonated beverages can cause bloating and increased feelings of fullness that become uncomfortable when gastric emptying is already delayed by semaglutide
By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
In this letter, we summarise the findings of the most recent studies that have reported the potential impact of GLP-1RAs on the residual gastric content (RGC), in light of an increased risk of aspiration pneumonia for patients undergoing general anaesthesia and/or deep sedation (Table 1)
Additional findings included: Safety profile consistent with incretin and amylin-based therapies Most adverse events were mild-to-moderate gastrointestinal events Both oral and subcutaneous formulations under development Phase 3 program planned to begin in H2 2026 According to Martin Holst Lange, Chief Scientific Officer of Novo Nordisk, the results reinforce the potential of zenagamtide to expand treatment options for both Type 2 Diabetes and obesity
Start with proper dosing knowledge Before working with any semaglutide product, understanding the full dosing landscape provides essential context
The injection site selection matters for absorption consistency, and understanding which injection sites optimize results is part of the learning curve